Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Distinguishing Tardive Dyskinesia From Other Drug-Induced Movement Disorders
  • CME
  • CE

Credits Available
Physicians: maximum of 1.0 AMA PRA Category 1 Credit
Registered Nurses: 1.0 Nursing contact hour
Pharmacists: 1.0 contact hour (0.1 CEUs)
Physician Assistants: maximum of 1.0 hour of AAPA Category 1 CME credit
Released: October 26, 2022 Expiration: October 25, 2023
Start Activity
Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from
Teva Pharmaceuticals
Stuart Isaacson, MD

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Differentiate characteristics of drug-induced movement disorders that can assist with accurate diagnosis
  • Compare and contrast treatment of different drug-induced movement disorders
  • Assess the safety and efficacy of VMAT2 inhibitors for tardive dyskinesia

Information on this Educational Activity

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Faculty

Stuart Isaacson, MD

Director
Parkinson's Disease and Movement Disorders Center of Boca Raton
Boca Raton, Florida
Clinical Associate Professor of Neurology
FIU Herbert Wertheim College of Medicine
Miami, Florida

Stuart Isaacson, MD: consultant/advisor/speaker: Neurocrine, Supernus, Teva.

Staff

Raquel Gaerlan

Director, Scientific Services

Raquel Gaerlan has no relevant financial relationships to disclose.
Amber Lemons, PharmD, BCPP

Director, Educational Strategy

Amber Lemons, PharmD, BCPP, has no relevant financial relationships to disclose.
Leslie Matson, MPA, PA-C
Leslie Matson, MPA, PA-C, has no relevant financial relationships to disclose.
Lisa Phipps, PharmD, PhD

Director, Science and Strategy, Neuroscience

Lisa Phipps, PharmD, PhD, has no relevant financial relationships to disclose.
Gabrielle Giacona

Associate Scientific Director

Gabrielle Giacona: individual publicly traded stocks/stock options: AstraZeneca, Moderna, Teva.
Jessie Gibson, PHD, RN, AGPCNP-BC
Jessie Gibson, PhD, RN, AGPCNP-BC: advisor/consultant/speaker: Teva.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

This program is intended for a multidisciplinary audience of neurologists, psychiatrists, primary care physicians, nurses, physician assistants/physician associates, pharmacists, and other members of the healthcare team involved in the management of patients with neurological and movement disorders.

Goal

The goal of this activity is to improve the knowledge, competence, and performance of learners to assess diagnostic considerations and new and emerging therapies for the treatment of neurological and movement disorders.

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education

Credit Designation

The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour.

Continuing Pharmacy Education

Credit Designation

CCO designates this continuing education activity for 1.0 contact hour (0.10 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number - JA4008176-0000-22-265-H01-P.

Type of Activity: Application

Upon successfully completing the post-test with a score of 65% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.

Physician Assistant/Physician Associate Continuing Medical Education

Clinical Care Options, LLC has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for maximum of 1.0 AAPA Category 1 CME credit. Approval is valid until October 25, 2023. PAs should only claim commensurate with the extent of their participation.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1.0 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from October 26, 2022, through October 25, 2023:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Distinguishing Tardive Dyskinesia From Other Drug-Induced Movement Disorders
  • CME
  • CE

Loading...
Watch this on-demand webcast of a live CCO presentation on distinguishing tardive dyskinesia from drug-induced parkinsonism and why it is important to treat sooner rather than later.
Stuart Isaacson, MD
Physicians: maximum of 1.0 AMA PRA Category 1 Credit
Registered Nurses: 1.0 Nursing contact hour
Pharmacists: 1.0 contact hour (0.1 CEUs)
Physician Assistants: maximum of 1.0 hour of AAPA Category 1 CME credit
Released: October 26, 2022 Expiration: October 25, 2023

Related Content

In this on-demand webcast, an expert faculty explores updates on identifying and managing tardive dyskinesia.

Leslie Citrome, MD, MPH Physicians: maximum of 1.0 AMA PRA Category 1 Credit Registered Nurses: 1.0 Nursing contact hour Pharmacists: 1.0 contact hour (0.1 CEUs) Physician Assistants: 1.0 AAPA Category 1 CME Credit Psychologists: 1.0 APA CE Credit Social Workers: 1.0 ACE CE Credit Released: January 23, 2023 Expired: January 22, 2024

In this on-demand webcast, an expert faculty explores updates on identifying and managing tardive dyskinesia.

Christoph U. Correll, MD Robert O. Cotes, MD Jonathan M. Meyer, MD Physicians: maximum of 1.0 AMA PRA Category 1 Credit Registered Nurses: 1.0 Nursing contact hour Pharmacists: 1.0 contact hour (0.1 CEUs) Physician Assistants: 1.0 AAPA Category 1 CME Credit Psychologists: 1.0 APA CE Credit Social Workers: 1.0 ACE CE Credit Released: January 4, 2023 Expired: January 3, 2024

A series of interactive eCases taking learners through examples of tardive dyskinesia management, from Clinical Care Options (CCO)

Stanley N. Caroff, MD Physicians: maximum of 1.0 AMA PRA Category 1 Credit Registered Nurses: 1.0 Nursing contact hour Pharmacists: 1.0 contact hour (0.1 CEUs) Physician Assistants: 1.0 AAPA Category 1 CME credit Psychologists: 1.0 APA CE Credit Social Workers: 1.0 ACE CE Credit Released: December 30, 2022 Expired: December 29, 2023

Expert presentation on tardive dyskinesia in patients with mood disorders, distinguishing tardive dyskinesia from drug-induced parkinsonism, and using VMAT2 inhibitors effectively, from Clinical Care Options (CCO)

Leslie Citrome, MD, MPH Physicians: maximum of 1.0 AMA PRA Category 1 Credit Registered Nurses: 1.0 Nursing contact hour Pharmacists: 1.0 contact hour (0.1 CEUs) Physician Assistants: 1.0 AAPA Category 1 CME credit Psychologists: 1.0 APA CE Credit Social Workers: 1.0 ACE CE Credit Released: December 29, 2022 Expired: December 28, 2023

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings